Global clinical trials activity decreased by 2.9% in Q2 2020, when compared with the same quarter in 2019, according to GlobalData.
Industry-sponsored trials accounted for a 46.1% share of overall activity in Q2 2020, an increase of 1.3% when compared with Q2 2019.
Non-industry-sponsored trials accounted for a 53.9% share of all clinical trials in Q2 2020, marking a decrease of 1.3% when compared with the same period in 2019.
Q2 2020 industry-sponsored clinical trials activity by therapy areas
Oncology was the leading therapy area for industry-sponsored clinical trials in Q2 2020, accounting for a 28.3% share of all trials.
This was followed by infectious disease with a 25.8% share, central nervous system with 10.8%, respiratory with 9.6% and metabolic disorders with 6.6%.
In Q2 2019, oncology led with a 27.9% share, followed by central nervous system with 14.4%, infectious disease with 10.1%, metabolic disorders with 9.4%, and cardiovascular with 8.6%.
|Industry-sponsored trials: Q2 2020 vs Q2 2019|
|Therapy Area||Q2 2019||Q2 2020||Activity|
|Central Nervous System||14.4%||10.8%|
|Genito Urinary System And Sex Hormones||2.7%||2.7%|
|Ear Nose Throat Disorders||1.1%||0.9%|
|Mouth and Dental Disorders||0.7%||0.4%|
|Non Malignant Disorders||0.3%||0.2%|
Most active therapy areas in non-industry-sponsored clinical trials
In Q2 2020 the leading therapy area for non-industry-sponsored clinical trials was infectious disease, accounting for a 34.9% share of all trials.
This was followed by oncology with a 20.0% share, central nervous system with 16.3%, respiratory with 10.1%, and cardiovascular with 7.0%.
In Q2 2019, central nervous system held the lead in non-industry-sponsored clinical trials with a 26.0% share, followed by oncology with 19.8%, cardiovascular with 9.6%, metabolic disorders with 7.8%, and gastrointestinal with 7.7%.
|Non-Industry-sponsored trials: Q2 2020 vs Q2 2019|
|Therapy Area||Q2 2019||Q2 2020||Activity|
|Central Nervous System||26.0%||16.3%|
|Genito Urinary System And Sex Hormones||3.6%||2.2%|
|Mouth and Dental Disorders||2.6%||1.4%|
|Ear Nose Throat Disorders||1.4%||1.1%|
|Non Malignant Disorders||0.5%||0.3%|
Asia-Pacific region has the most activity for industry-sponsored clinical trials
Asia-Pacific was the most active region for industry-sponsored clinical trials activity in Q2 2020 with a 47.9% share, compared with 52.0% in Q2 2019.
North America was the second most active region with a 34.7% share in Q2 2020, up from 33.3% in Q2 2019, followed by Europe with a 28.0% share in Q2 2020, down from 29.2% in Q2 2019.
Single country studies held an 85.4% share in industry-sponsored clinical trials in Q2 2020, compared with 84.1% in Q2 2019. Multinational trials accounted for 14.6% in Q2 2020, against 15.9% in Q2 2019.
Regional activity for non-industry-sponsored clinical trials
Asia-Pacific saw the most non-industry-sponsored clinical trial activity in Q2 2020 with a 41.0% share, down from 54.4% in Q2 2019.
Middle East and Africa held the second position with a 19.9% share in Q2 2020, compared with 16.1% in Q2 2019. This was followed by North America with a 19.9% share in Q2 2020, as against 16.4% in Q2 2019.
Single country studies accounted for 98.8% share of non-industry-sponsored clinical trials in Q2 2020, compared with 98.9% in Q2 2019. Multinational trials accounted for a 1.2% share in Q2 2020, up from 1.1% in Q2 2019.
Clinical trials by phase in Q2 2020
Phase II trials outnumbered all other studies with a 39.5% share for industry-sponsored trials in Q2 2020, compared with 33.8% in Q2 2019.
The share of Phase I trials stood at 30.0% in Q2 2020, down from 37.2% in Q2 2019. Phase III trials increased to 20.0% in Q2 2020, compared with 17.2% in Q2 2019, followed by Phase IV trials with a 10.5% share in Q2 2020, against 11.8% in Q2 2019.
For non-industry-sponsored clinical trials, Phase II activity decreased to a 43.7% share in Q2 2020, compared with 47.7% in Q2 2019.
Phase III trials were the second most active with a 23.8% share in Q2 2020, compared with 18.7% in Q2 2019. Phase IV trials held an 18.1% share in Q2 2020, against 19.5% in Q2 2019, followed by Phase I trials with a 14.5% share in Q2 2020, over 14.1% in Q2 2019.
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.